Literature DB >> 7014827

A standard approach to compiling clinical pharmacokinetic data.

L B Sheiner, L Z Benet, L A Pagliaro.   

Abstract

A standard format for a Clinical Pharmacokinetic Summary is proposed. It consists of a heading, tables, notes, and references for each drug reviewed. The table presents a unified and logical set of clinically useful population pharmacokinetic parameters. They concern four major areas: absorption, distribution, elimination, and the relationship of concentration to effect. Within each major group, parameters dealing with extents and rates of processes are given. Each such parameter is really two: a population mea value (for example, average volume of distribution) and the standard deviation of individual values about this mean. The first value allows individual predictions of dosage or drug level to be made; the second allows computation of the likely proximity of subsequently observed quantities to those predictions. The table presents single consensus values for each population parameter, rather than a list of values. A procedure for computing these consensus values, and for revising them in the light of new data, or reinterpreted old data, is given. Examples of Summaries are given. The method appears applicable to a variety of drugs. We suggest our approach as a standard one for preparing Clinical Pharmacokinetic Summaries, and urge our colleagues to consider it for that purpose.

Mesh:

Substances:

Year:  1981        PMID: 7014827     DOI: 10.1007/bf01059343

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  414 in total

1.  Effects of oral propranolol in normal subjects.

Authors:  M M LeWinter; M H Crawford; J S Karliner; R A ORourke
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

2.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

3.  A radioreceptor assay for propranolol.

Authors:  J P Bilezikian; D E Gammon; C L Rochester; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

4.  Identification of the major urinary metabolite of alprenolol in man, dog and rat.

Authors:  N O Bodin
Journal:  Life Sci       Date:  1974-02-16       Impact factor: 5.037

5.  Identification by gas chromatography-mass spectroscopy of dihydrodigoxin--a metabolite of digoxin in man.

Authors:  E Watson; D R Clark; S M Kalman
Journal:  J Pharmacol Exp Ther       Date:  1973-02       Impact factor: 4.030

6.  Pharmacokinetic and pharmacodynamic studies with long-acting propranolol.

Authors:  J McAinsh; N S Baber; R Smith; J Young
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  Human serum and myocardium digoxin.

Authors:  G Härtel; K Kyllönen; E Merikallio; K Ojala; V Manninen; P Reissell
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

8.  Digoxin bioavailability: formulations and rates of infusions.

Authors:  F I Marcus; J Dickerson; S Pippin; M Stafford; R Bressler
Journal:  Clin Pharmacol Ther       Date:  1976-09       Impact factor: 6.875

9.  The measurement of digitoxin in human serum by radioimmunoassay.

Authors:  G C Oliver; B M Parker; D L Brasfield; C W Parker
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

10.  Relation between plasma and red-cell electrolyte concentrations and digoxin levels in children.

Authors:  M W Loes; S Singh; J E Lock; B L Mirkin
Journal:  N Engl J Med       Date:  1978-09-07       Impact factor: 91.245

View more
  11 in total

Review 1.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

2.  Mean time and first-pass metabolism.

Authors:  D Brockmeier; J Ostrowski
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 3.  Discrepancies between pharmacokinetic studies of amitriptyline.

Authors:  P Schulz; P Dick; T F Blaschke; L Hollister
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

4.  Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults.

Authors:  Raju Kanukula; Abdul Salam; Anthony Rodgers; Bishoy Kamel
Journal:  Clin Pharmacokinet       Date:  2021-01-11       Impact factor: 6.447

5.  Rapid achievement of a serum concentration plateau of digoxin through controlled infusion.

Authors:  M Weiss; W Sziegoleit; A Fahr; W Förster
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  Model-independent assessment of accumulation kinetics based on moments of drug disposition curves.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of metformin.

Authors:  Garry G Graham; Jeroen Punt; Manit Arora; Richard O Day; Matthew P Doogue; Janna K Duong; Timothy J Furlong; Jerry R Greenfield; Louise C Greenup; Carl M Kirkpatrick; John E Ray; Peter Timmins; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

Review 8.  Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

Authors:  Bishoy Kamel; Garry G Graham; Kenneth M Williams; Kevin D Pile; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2017-05       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 10.  Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.

Authors:  Facundo Garcia-Bournissen; Jaime Altcheh; Norberto Giglio; Guido Mastrantonio; Carlos Omar Della Védova; Gideon Koren
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.